Reuters logo
3 个月前
BRIEF-U.S. FDA approves Merck's Keytruda chemo combo for lung cancer
2017年5月10日 / 晚上10点07分 / 3 个月前

BRIEF-U.S. FDA approves Merck's Keytruda chemo combo for lung cancer

May 10 (Reuters) - Merck & Co Inc

* Fda approves Merck's Keytruda® (pembrolizumab) as first-line combination therapy with pemetrexed and carboplatin for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-l1 expression

* Merck & Co Inc - Under FDA's accelerated approval regulations, this indication is approved based on tumor response rate and progression-free survival Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below